Glomerulonephritis

Zusammenfassung

Glomerulonephritiden stellen eine heterogene Krankheitsgruppe mit unterschiedlicher Pathophysiologie dar. Eine definitive Diagnose ist nur durch eine Nierenbiopsie möglich. Initial muss immer zwischen einer primären und sekundären Glomerulonephritisformen unterschieden werden. Bei sekundären Formen ist die Glomerulonephritis nach Therapie der Grunderkrankung häufig regredient. In der Therapie-Auswahl kommt der Abschätzung der individuellen Prognose eine hohe Bedeutung zu. Unter optimaler sogenannter supportiver Therapie unter anderem mit Kontrolle von Blutdruck, Senkung der Proteinurie, Nikotinkarenz und diätetischen Maßnahmen kann häufig ein Progress verlangsamt oder sogar verhindert werden. Häufige Glomerulonephritis-Typen in West-Europa umfassen die IgA-Nephropathie, membranöse Glomerulonephritis und die rapid progressive Glomerulonephritis (RPGN).

Abstract

Glomerulonephritides represent a heterogenous group of diseases with different pathophysiology. A definitive diagnosis requires a renal biopsy. The differentiation between a primary or secondary glomerulonephritis is of major clinical relevance, because most secondary forms resolve once the primary cause is treated properly. Assessing the individual prognosis of a patient is of central importance in choosing the best therapeutic regimen. By optimizing the so-called supportive therapy with the control of blood pressure, reduction of proteinuria, cessation of smoking and dietary measures the loss of kidney function can often be slowed down or even stopped. The most common types of glomerulonephritis in Western Europe comprise IgA-nephropathy, membranous glomerulonephritis and rapidly progressive glomerulonephritis (RPGN).

Schlüsselwörter

glomeruläre Erkrankung - Glomerulonephritis - supportive Therapie - Immunsuppression - Proteinurie - GFR

Keywords

glomerular disease - glomerulonephritis - supportive therapy - immunosuppression - proteinuria - GFR

• Literatur

• 1 Baigent C, Landray MJ, Reich C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
• 2 Beck Jr LH, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21
• 3 Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821
• 4 Floege J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol 2011; 22: 1785-1794
• 5 Floege J. The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches?. Am J Kidney Dis 2011; 58: 992-1004
• 6 Goraya N, Simoni J, Jo C et al. Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney international 2012; 81: 86-93
• 7 Hoxha E, Kneissler U, Stege G et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney international 2012; 82: 797-804
• 8 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 340-414
• 9 KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney international 2012; 2 (Suppl. 02) 139-274
• 10 Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553
• 11 Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213